Immunosuppression with Rituximab in Glomerular Diseases in Adults: Who, How and When?

Immunosuppression with Rituximab in Glomerular Diseases in Adults: Who, How and When?

Rituximab, a monoclonal antibody with the ability to bind itself to CD20, leads to a rapid depletion of B-cells (in around 24-72 hours), limiting antibody formation. The marker CD20 does not exist in any other cell type, which makes the action of rituximab specific. This antibody has been used in a...

Full description

Bibliographic Details
Main Authors: Raquel Pereira Sousa Pinto, Carolina dos Reis Ferreira, André Sotero Araújo Ferreira, Joaquim Manuel Leal Milheiro, Catarina Maia da Veiga, Maria Luísa de Lemos Ferreira Casimiro da Costa, Andreia Raquel Dias da Silva, Carla Maria Pereira Lima, Sérgio José da Silva Lemos
Format: Article
Language:English
Published: Publicações Ciência e Vida 2023-06-01
Series:Revista Portuguesa de Nefrologia e Hipertensão
Subjects:
immunosuppressive agents
kidney diseases/drug therapy
rituximab/therapeutic use
Online Access:https://spnefro.pt/_doi/reference/cbe0a333-3a31-4926-a522-7e725cad311a

Internet

https://spnefro.pt/_doi/reference/cbe0a333-3a31-4926-a522-7e725cad311a

Similar Items